SK3 Group Completes Beta Testing of Broad Use T-Hydrocan(TM) and Prepares for Distribution to Collectives and Pharmajanes.com
March 12 2014 - 7:45AM
Marketwired
SK3 Group Completes Beta Testing of Broad Use T-Hydrocan(TM) and
Prepares for Distribution to Collectives and Pharmajanes.com
LOS ANGELES, CA--(Marketwired - Mar 12, 2014) - SK3 Group, Inc.
(OTC Pink: SKTO) (PINKSHEETS: SKTO), doing business as Medical
Greens, through its subsidiary Berkely Bio-Organic Research
Laboratories, has completed beta-testing of the initial offering in
its recently announced phyto-cannabinoid product line,
T-Hydrocan™. T-Hydrocan™ RMC 40 contains 40 mg. of refined
mixed cannabinoids which have been extracted from cannabis flowers
utilizing solvents approved for food contact, refined via numerous
filtration and separation processes to remove as many of the
non-cannabinoid elements as possible, and pressed into a chewable
tablet.
Unlike Medical Greens' non-psychoactive Dharmanol™ product line,
T-Hydrocan™ RMC 40 contains fully-activated (decarboxylated) THC,
producing the classic effects of medical marijuana via an
orally-consumed tablet.
"While we are most excited about the possibilities of the
non-psychoactive cannabinoids, the great bulk of the research, as
well as the majority of the scientific knowledge of the medicinal
healing effects ascribed to cannabis medicine, come from research
performed on psychoactive THC. Orally-consumed doses of various
types and strengths of traditional cannabis extracts have shown
substantial efficacy in treating pain, anxiety, insomnia, anorexia,
as well as numerous other conditions. T-Hydrocan RMC 40
tablets have been designed to benefit those seeking relief from
these, and many other conditions that have been successfully
treated with medicinal cannabis," said David Hoye of Berkeley
Bio-Organic Research Laboratory.
Each tablet of T-Hydrocan™RMC 40 contains the following
ingredients specifically:
1. Microcrystalline cellulose; 2. Magnesium stearate
(vegetable source); 3. Sucrose; 4. Dextrin;
5. Natural flavorings; 6. Vitamin C as ascorbic acid (a
preservative); and 7. Purified oil of cannabis / hemp
containing 40 mg. of refined mixed phyto-cannabinoids.
T-Hydrocan™ RMC 40 tablets will now be packaged and made
available to qualified California medical patients through the
network of medicinal collectives serviced and managed by Medical
Greens, as well as through the Pharmajanes.com ordering
platform.
Several other products in the T-Hydrocan™ product line are being
prepared for beta-testing and will soon follow the release of
T-Hydrocan™ RMC 40. On the other end of the spectrum from the RMC
(refined mixed cannabinoids) offering, T-Hydrocan™ Whole Plant,
will contain as many of the over 400 natural medicinal elements of
the cannabis/hemp plant as possible, removing only the fiber. Many
patients have found the "whole plant" approach preferable to
eliminating any possible medicinal element that is present in the
natural plant when it is processed into an orally ingested
medicine.
Following T-Hydrocan™ Whole-Plant will be T-Hydrocan™ Citrolene™
tablets, which will combine the effects of active cannabinoids with
those of the natural terpene d-Limonene. This natural medicine,
d-Limonene, is found in cannabis/hemp as well as in many other
plants. It has relaxing, anti-anxiety, and anti-spasmodic effects,
as it binds with the same receptors in the human body as does the
benzodiazapines Valium and Xanax, but has been shown to be
non-toxic and non-addictive.
"We are pleased to have completed this step in the development
process and are looking forward to seeing T-Hydrocan™ RMC-40
tablets available through our managed collectives and
Pharmajanes.com within the next 60 days," said Artemus Mayor,
President of Medical Greens. "This development demonstrates
our commitment to medical cannabis focused products to deliver more
of what our patients want when they want it."
About SKTO SK3 is a healthcare logistics and fulfillment
consultancy doing business as Medical Greens™ and focused on the
delivery of alternative care and medicine. With seasoned
management, breakthrough technology and best practices, SK3 brings
standardization and transparency to this rapidly growing segment of
the alternative care field.
FDA Statement The statements in this document have not been
evaluated or approved by the FDA. The products and statements
referenced in this document are not intended to diagnose, treat,
cure, or prevent any disease.
Safe Harbor Statement This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. These forward-looking statements are based on the
current plans and expectations of management and are subject to a
number of uncertainties and risks that could significantly affect
the company's current plans and expectations, as well as future
results of operations and financial condition. A more extensive
listing of risks and factors that may affect the company's business
prospects and cause actual results to differ materially from those
described in the forward-looking statements can be found in the
reports and other documents filed by the company with the
Securities and Exchange Commission. The company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Relations SK3 Group, Inc. d.b.a Medical Greens
investors@medicalgreens.com
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Mar 2024 to Apr 2024
SK3 (CE) (USOTC:SKTO)
Historical Stock Chart
From Apr 2023 to Apr 2024